GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipca Laboratories Ltd (BOM:524494) » Definitions » EV-to-EBITDA

Ipca Laboratories (BOM:524494) EV-to-EBITDA : 25.07 (As of May. 14, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Ipca Laboratories EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ipca Laboratories's enterprise value is ₹338,747 Mil. Ipca Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹13,511 Mil. Therefore, Ipca Laboratories's EV-to-EBITDA for today is 25.07.

The historical rank and industry rank for Ipca Laboratories's EV-to-EBITDA or its related term are showing as below:

BOM:524494' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.84   Med: 18.75   Max: 74.99
Current: 25.07

During the past 13 years, the highest EV-to-EBITDA of Ipca Laboratories was 74.99. The lowest was 11.84. And the median was 18.75.

BOM:524494's EV-to-EBITDA is ranked worse than
74.33% of 705 companies
in the Drug Manufacturers industry
Industry Median: 14.58 vs BOM:524494: 25.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), Ipca Laboratories's stock price is ₹1297.75. Ipca Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹22.250. Therefore, Ipca Laboratories's PE Ratio for today is 58.33.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Ipca Laboratories EV-to-EBITDA Historical Data

The historical data trend for Ipca Laboratories's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipca Laboratories EV-to-EBITDA Chart

Ipca Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.76 18.27 14.73 19.23 18.95

Ipca Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.02 18.95 16.92 22.14 20.91

Competitive Comparison of Ipca Laboratories's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipca Laboratories's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ipca Laboratories's EV-to-EBITDA falls into.



Ipca Laboratories EV-to-EBITDA Calculation

Ipca Laboratories's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=338746.549/13510.6
=25.07

Ipca Laboratories's current Enterprise Value is ₹338,747 Mil.
Ipca Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹13,511 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipca Laboratories  (BOM:524494) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ipca Laboratories's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1297.75/22.250
=58.33

Ipca Laboratories's share price for today is ₹1297.75.
Ipca Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹22.250.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Ipca Laboratories EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ipca Laboratories's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipca Laboratories (BOM:524494) Business Description

Traded in Other Exchanges
Address
125, Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a specialty and generic drug manufacturing company. The company's principal activity is Development, Manufacturing and Marketing of Pharmaceuticals Products. The company operates multiple subsidiaries with revenue generation split roughly between India and the rest of the world. Ipca's products are exported to more than 100 countries across the globe. Ipca has only one reportable primary business segment, pharmaceuticals.

Ipca Laboratories (BOM:524494) Headlines

No Headlines